SecBot SecBot
8-K ·Filed Feb 25, 2026

ACAD

ACADIA PHARMACEUTICALS INC
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001193125-26-071674
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of raised guidance, strong non-GAAP revenue growth, and upcoming R&D catalysts (remlifanserin Phase 2 readout in Q3 2026) suggests continued momentum. Traders should monitor DAYBUE STIX launch execution in Q2 and pipeline developments as potential upside catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$24.64
T+0 close · Feb 25, 2026 · via day close
Latest settled
−13.47%
T+60 · $21.32
Vs SPY
−21.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $24.64entry
  2. T+1 · 9mo ago −0.32%α +0.13% · $24.56
  3. T+5 · 9mo ago −9.09%α −7.96% · $22.40
  4. T+20 · 8mo ago −12.87%α −6.46% · $21.47
  5. T+60 · 6mo ago −13.47%α −21.22% · $21.32
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Acadia Pharmaceuticals reported strong fourth quarter and full year 2025 results, with GAAP revenue growth of 9% and 12% respectively, and non-GAAP adjusted revenue growth of 16% and 14%. The company raised full year 2026 revenue guidance to $1.22–1.28 billion, driven by continued momentum in NUPLAZID and DAYBUE sales, while also announcing a strategic sales force expansion and upcoming catalysts in its R&D pipeline.

Key Financial Metrics

Revenue
$1.1B
+12.0% YoY
EPS
$2.30
Guidance
$1.22B-$1.28B
raised

Key Facts

  • Q4 2025 GAAP total revenue: $284 million (9% YoY growth); full year 2025 GAAP revenue: $1.07 billion (12% YoY growth)
  • Q4 2025 non-GAAP adjusted revenue: $298 million (16% YoY growth); full year 2025: $1.08 billion (14% YoY growth)
  • NUPLAZID GAAP net sales: $174 million in Q4 2025; non-GAAP adjusted: $189 million (17% YoY growth)
  • DAYBUE GAAP net sales: $110 million in Q4 2025 (13% YoY growth)
  • Full year 2026 revenue guidance: $1.22–1.28 billion, representing 14–19% growth over 2025
  • Net income: $274 million in Q4 2025 ($1.60 diluted EPS), up from $144 million ($0.86) in Q4 2024, including a $250 million non-cash tax benefit
  • Cash and investments: $820 million at year-end 2025, up from $756 million in 2024

Financial Impact

Revenue growth accelerated in 2025 with full year guidance implying double-digit top-line expansion in 2026. Non-GAAP revenue growth of 14–16% reflects strong underlying demand, particularly for DAYBUE (13% Q4 growth) and NUPLAZID (17% non-GAAP growth).

revenueepscashFlow

Segment Breakdown

SegmentRevenueGrowth
NUPLAZID$680.1M+11.7%
DAYBUE$391.4M+12.4%

Risk Factors

  • GAAP revenue growth was partially impacted by a $20 million non-recurring IRA rebate accrual adjustment for NUPLAZID, which could resurface in future periods
  • SG&A expenses increased to $549 million in 2025 and are guided to $660–700 million in 2026, which may pressure margins if revenue growth slows
  • Future tax benefits may not be recurring, and core profitability should be assessed excluding the $250 million one-time benefit

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-071674
Document: acad-20260225.htm0001193125-26-071674
Document: 0001193125-26-071674-index-headers.html0001193125-26-071674
Document: 0001193125-26-071674-index.html0001193125-26-071674
Document: 0001193125-26-071674.txt0001193125-26-071674
CONTEXT: Previous Earnings (2026-02-25)0001193125-26-071674

Track record

14 reports on ACAD

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.01% at T+20 after the May 6, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $18.28 Now $18.67 +2.13% settles Dec 9
  2. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $21.24 Now $18.67 −12.10% settles Dec 4
  3. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $20.57 Now $18.67 −9.24% settles Dec 2
  4. Oct 23, 202624d ago 8-K Neutral 3/10 Entry $19.74 Now $18.67 −5.42% settles Nov 23
  5. Sep 24, 20267w ago 8-K Bullish 6/10 Entry $20.68 to $19.73 Now $18.67 −9.72% ▼ −4.59% −3.12% vs SPY
  6. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $27.52 to $19.41 Now $18.67 −32.16% ▼ −29.47% −31.73% vs SPY
  7. Aug 16, 202613w ago Institutional Cluster Mixed 5/10 Entry $29.01 to $26.76 Now $18.67 −35.64% ▼ −7.76% −5.78% vs SPY
  8. Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $29.39 to $27.58 Now $18.67 −36.47% ▼ −6.16% −5.24% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $21.39 to $26.41 Now $18.67 +12.72% ▼ −23.47% −21.58% vs SPY
  10. May 6, 202627w ago 8-K Bearish 6/10 Entry $22.56 to $21.43 Now $18.67 +17.24% ▲ +5.01% +8.14% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 8h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026